Reagents
DFMO + erlotinib（DFMO与erlotinib联合方案）（文献参考）
This content is currently available only in Chinese. 此内容暂仅提供中文。 查看中文内容 · Chinese version
- Composition
- DFMO（difluoromethylornithine，α-二氟甲基鸟氨酸）与erlotinib（厄洛替尼）联合方案（为药物联合组合，非单一化合物）
- Use information
- 用于家族性腺瘤性息肉病（FAP）的结直肠息肉化学预防联合方案。文献综述报道sulindac联合erlotinib可使FAP患者结直肠息肉负荷降低70%（95% CI 29%-109%）；DFMO联合celecoxib与单用celecoxib相比无显著额外获益。证据来源于FAP患者的临床试验。
Reference, supply and purchase path
No verified catalog mapping exists for this reagent; reference status: unknown.
No listed sale configuration is published here. This states neither discontinuation nor current stock.
Store-homepage entry for consultation only — not a direct purchase link.
Bulk pricing and availability inquiry
Submitting an inquiry does not place an order or confirm a purchase.
No exact merchant mapping is verified for this reagent; the reference below is an internal inquiry identifier only.
Reagent：DFMO + erlotinib（DFMO与erlotinib联合方案）（文献参考）
Stable id：reagent-520（Internal inquiry reference (site id; not a merchant catalog or manufacturer SKU)）
Specification: unknown (not verified)